argus

Glenmark Pharmaceuticals ltd

NSE: GLENMARKINE935A0103569,546 Cr

Timeline

Time (IST)TypeMEventSrc
11 Dec, 08:42 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial".nse
01 Dec, 08:54 amUpdate on the Company's Chhatrapati Sambhajinagar (Aurangabad) Facilitynse
27 Nov, 10:15 amGlenmark Pharmaceuticals Ltd - 532296 - Update On The Company''s Monroe, North Carolina (USA) Facilitybse
27 Nov, 10:15 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility".nse
25 Nov, 09:00 amGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
25 Nov, 08:59 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Glenmark Pharmaceuticals Announces Launch of Nebzmart® GFB Smartules® and GlenmarkAirz® FB Smartules®, World s First Nebulized Triple Therapy for COPD".nse
19 Nov, 05:17 pmGlenmark Pharmaceuticals Limited has informed the Exchange about Transcriptnse
19 Nov, 05:17 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
18 Nov, 02:40 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Nov, 02:40 pmGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2025, titled "Cosmo and Glenmark Announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe ".nse
17 Nov, 01:01 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
17 Nov, 01:01 pmGlenmark Pharmaceuticals Limited has informed the Exchange about Link of Recordingnse
14 Nov, 06:12 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
14 Nov, 06:12 pmGlenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentationnse
14 Nov, 06:04 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
14 Nov, 06:04 pmPress Release and Management Discussion & Analysis - Q2FY26 Resultsnse
14 Nov, 05:56 pmGlenmark Pharmaceuticals Limited has submitted to the Exchange, Unaudited Financial Results (Standalone and Consolidated) for the Second Quarter and Half Yearended 30th September, 2025.nse
14 Nov, 03:34 pmGlenmark Pharmaceuticals Limited has informed the Exchange about Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015nse
10 Nov, 03:30 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
10 Nov, 03:30 pmGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2025, titled "Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership".nse
04 Nov, 08:59 amGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Nov, 08:57 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial".nse
03 Nov, 05:34 pmGlenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2025bse
01 Nov, 12:07 pmGlenmark Pharmaceuticals Limited has informed the Exchange about Completion of transfer of Company's Consumer Care businessnse
23 Oct, 09:15 amGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
23 Oct, 09:14 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials".nse
26 Sept, 11:09 amGlenmark Pharmaceuticals Limited has informed the Exchange that the Board approves Dividend and as intimated earlier Record date for the purpose of Dividend is 03-Oct-2025.nse
26 Sept, 11:04 amGlenmark Pharmaceuticals Ltd - 532296 - Corporate Action-Board approves Dividendbse
26 Sept, 10:48 amGlenmark Pharmaceuticals Ltd - 532296 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 26Th September, 2025bse
26 Sept, 10:48 amGlenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on September 26, 2025, declared Interim Dividend of 2.5 per equity share.nse
24 Sept, 03:39 pmGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
24 Sept, 03:39 pmGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 24, 2025, titled "Glenmark Strengthens Oncology Portfolio with Hengrui s HER2 Targeting ADC For Multiple Regions".nse
22 Sept, 05:44 pmGlenmark Pharmaceuticals Limited has informed the Exchange that Revised Record date for the purpose of Dividend is 03-Oct-2025.nse
22 Sept, 05:40 pmGlenmark Pharmaceuticals Ltd - 532296 - Revision In Intimation Of Record Date For Interim Dividendbse
22 Sept, 04:11 pmGlenmark Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 30-Sep-2025.nse
22 Sept, 04:06 pmGlenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving Payment Of Interim Dividendbse
19 Sept, 10:33 amGlenmark Pharmaceuticals Limited has informed the Exchange about Credit Ratingnse
19 Sept, 10:29 amGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
15 Sept, 05:21 pmGlenmark Pharmaceuticals Limited has informed the Exchange about update on Transfer of the Company's Consumer Care businessnse
09 Sept, 08:53 amGlenmark Pharmaceuticals Ltd - 532296 - Intimation Regarding Upfront Payment Receivedbse
09 Sept, 08:48 amGlenmark Pharmaceuticals Limited has informed the Exchange about General Updatesnse
05 Sept, 09:48 amGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
05 Sept, 09:46 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 05, 2025, titled "Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer".nse
02 Sept, 10:29 amGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 02, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials".nse
02 Sept, 10:27 amGlenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse